课题基金 / 基金详情

A Novel Biomarker Discovery Strategy Combining Primary Tumour Xenograft Models and Glyco-Capture of Secreted Proteins

A Novel Biomarker Discovery Strategy Combining Primary Tumour Xenograft Models and Glyco-Capture of Secreted Proteins
结合原发性肿瘤异种移植模型和分泌蛋白的糖捕获的新型生物标志物发现策略
批准号：
290638
负责人：
Kislinger Thomas
金额：
$25.61万
依托单位：
University Health Network (Toronto)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2013
资助国家：
加拿大
项目状态：
已结题
起止时间：
2013-09-01 至 2016-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=290638&lang=en
关键词：
Biomarker Ovarian Cancer Proteomics Recurrence Xenograft

项目摘要

项目成果

Kislinger Thomas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Epithelial ovarian cancer (EOC) is among the most common malignancies in women worldwide. In 2009, there were an estimated 21,000 new cases in North America, and it was the 5th leading cause of cancer-mortality in women. As for most cancers, disease stage
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chair Tier 1
  • 批准号：
    453810
  • 项目类别：
  • 资助金额：
    $101.99万
  • 财政年份：
    2020
  • 负责人：
    Kislinger Thomas
  • 依托单位：
    University of Toronto
The Ovarian Cancer Glycoproteome: Biomarker Discovery and Therapeutic Targets
Identifying the molecular landscape of the triple negative breast cancer cell surface proteome – an avenue for new therapies
Proteogenomics Panorama of Localized Prostate Cancers
海外基金